and its subsidiaries had the operation results for the three-month period ended March 31, 2018 with the following details: unit: THB million 2018 2017 Change (THB million) Change (%) Revenue from Sales

domestic sales 24.2% and export sales 75.8%. Gross profit was down from 33.6% to 25.8% due to low margin sale to B2B coupled with the increase in raw material and energy costs. Total expense was Baht 504.6

) % Change Revenues from sales and services 292.80 161.61 131.19 81.17 Other revenues 5.03 5.27 (0.24) (4.55) Total revenues 297.84 166.88 130.96 78.47 Costs of sales and services 212.57 126.58 85.99 67.93

Increase (Decrease) % Change Revenues from sales and services 344.69 178.62 166.07 92.97 Other revenues 3.05 1.09 1.96 179.82 Total revenues 347.74 179.71 168.03 93.50 Costs of sales and services 245.56

139 million or 25.89% up from 2Q2016. The consolidated gross profit margin contributed of 16.32% in 2Q2017, increased from 13.83% in 2Q2016 predominantly from cost advantage from lower major feed

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

sales from lower EDC purchase plus greater ECH sales from the additional volume to China, Taiwan and Indian accounts. The share of domestic and export sales have no significant change comparing to the

from Consolidated Q2/ 2019 Q2/ 2018 Change Financial Statements (Million Baht) (%) (Million Baht) (%) (%) Revenue from Sales 1,302.1 100.0 % 1,286.9 100.0 % 1.2 % Cost of Sales (937.5) (72.0 %) (912.6

declined yoy whereas revenue per head remained on the rise. The increase of revenue per head was Operation : Consolidated Profit & Loss Statement 3Q 3Q % 9 mth 9 mth % Unit : THB million 2019 2018 change

, 2019 as follow: Consolidated Q3/ 2019 Q3/ 2018 Change Financial Statements (Million Baht) (%) (Million Baht) (%) (%) Revenue from Sales 1,267.6 100.0 % 1,454.5 100.0 % (12.8 %) Cost of Sales (926.0